SG11202010450VA - Compounds - Google Patents

Compounds

Info

Publication number
SG11202010450VA
SG11202010450VA SG11202010450VA SG11202010450VA SG11202010450VA SG 11202010450V A SG11202010450V A SG 11202010450VA SG 11202010450V A SG11202010450V A SG 11202010450VA SG 11202010450V A SG11202010450V A SG 11202010450VA SG 11202010450V A SG11202010450V A SG 11202010450VA
Authority
SG
Singapore
Prior art keywords
compounds
Prior art date
Application number
SG11202010450VA
Other languages
English (en)
Inventor
Paul STUPPLE
Helen Lagiakos
Benjamin Morrow
Richard Foitzik
Catherine Hemley
Michelle Camerino
Ylva Bozikis
Scott Walker
Original Assignee
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctxt Pty Ltd filed Critical Ctxt Pty Ltd
Publication of SG11202010450VA publication Critical patent/SG11202010450VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
SG11202010450VA 2018-06-20 2019-06-20 Compounds SG11202010450VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1810092.5A GB201810092D0 (en) 2018-06-20 2018-06-20 Compounds
PCT/EP2019/066337 WO2019243491A1 (en) 2018-06-20 2019-06-20 Compounds

Publications (1)

Publication Number Publication Date
SG11202010450VA true SG11202010450VA (en) 2021-01-28

Family

ID=63042663

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010450VA SG11202010450VA (en) 2018-06-20 2019-06-20 Compounds

Country Status (39)

Country Link
US (2) US20200039945A1 (es)
EP (2) EP3810602B1 (es)
JP (1) JP2021529738A (es)
KR (1) KR20210022655A (es)
CN (1) CN112334466A (es)
AR (1) AR114972A1 (es)
AU (1) AU2019289888A1 (es)
BR (1) BR112020025869A2 (es)
CA (1) CA3101238A1 (es)
CL (1) CL2020003219A1 (es)
CO (1) CO2020014586A2 (es)
CR (1) CR20210032A (es)
CU (1) CU20200096A7 (es)
DK (1) DK3810602T3 (es)
DO (1) DOP2020000249A (es)
EA (1) EA202092451A1 (es)
EC (1) ECSP20075270A (es)
ES (1) ES2967983T3 (es)
FI (1) FI3810602T3 (es)
GB (1) GB201810092D0 (es)
GE (1) GEP20227403B (es)
HR (1) HRP20231467T1 (es)
HU (1) HUE064744T2 (es)
IL (1) IL279554A (es)
LT (1) LT3810602T (es)
MA (1) MA52948B1 (es)
MD (1) MD3810602T2 (es)
MX (1) MX2020012723A (es)
NI (1) NI202000092A (es)
PE (1) PE20210181A1 (es)
PH (1) PH12020500673A1 (es)
PL (1) PL3810602T3 (es)
PT (1) PT3810602T (es)
RS (1) RS64932B1 (es)
SG (1) SG11202010450VA (es)
SI (1) SI3810602T1 (es)
TW (1) TWI826471B (es)
UY (1) UY38270A (es)
WO (1) WO2019243491A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471271A1 (en) 2017-10-16 2019-04-17 Acoustical Beauty Improved convolutions of digital signals using a bit requirement optimization of a target digital signal
JP7352662B2 (ja) * 2019-06-18 2023-09-28 ファイザー・インク ベンゾイソオキサゾールスルホンアミド誘導体
AU2020295006B2 (en) * 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
JP2022540434A (ja) * 2019-07-12 2022-09-15 キャノピー グロウス コーポレイション カンナビノイド誘導体
BR112023000687A2 (pt) 2020-07-15 2023-02-07 Pfizer Métodos e combinações de inibidores de kat6 para o tratamento de câncer
EP4341259A1 (en) * 2021-05-21 2024-03-27 Aurigene Oncology Limited Fused isoxazolyl compounds as kat6a inhibitors
EP4368620A1 (en) * 2021-07-05 2024-05-15 Hangzhou Innogate Pharma Co., Ltd. Compound serving as kat6 inhibitor
CA3228411A1 (en) 2021-08-10 2023-02-16 Xiaomin Zhang Sulfonamide derivative, preparation method therefor and medical use thereof
TW202334163A (zh) * 2021-11-16 2023-09-01 香港商英矽智能科技知識產權有限公司 離胺酸乙醯基轉移酶6a (kat6a)抑制劑及其用途
WO2023114710A1 (en) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
US20230303580A1 (en) 2022-03-28 2023-09-28 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
US20230416240A1 (en) * 2022-06-16 2023-12-28 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0961780B1 (en) 1997-02-12 2007-04-11 Electrophoretics Limited Protein markers for lung cancer and use thereof
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR20080015482A (ko) 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
WO2001060814A2 (en) 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
DK2385938T3 (en) * 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
MX2015010775A (es) * 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
EP3683222B1 (en) * 2014-04-23 2021-10-06 Mitsubishi Tanabe Pharma Corporation Novel bicyclic or tricyclic heterocyclic compound
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2018102419A1 (en) * 2016-11-29 2018-06-07 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
JP7352662B2 (ja) * 2019-06-18 2023-09-28 ファイザー・インク ベンゾイソオキサゾールスルホンアミド誘導体

Also Published As

Publication number Publication date
PH12020500673A1 (en) 2021-05-31
AR114972A1 (es) 2020-11-11
TW202016103A (zh) 2020-05-01
DK3810602T3 (da) 2023-12-11
KR20210022655A (ko) 2021-03-03
CO2020014586A2 (es) 2021-03-08
ES2967983T3 (es) 2024-05-06
EP4335439A3 (en) 2024-05-15
US20220153710A1 (en) 2022-05-19
MD3810602T2 (ro) 2024-03-31
TWI826471B (zh) 2023-12-21
ECSP20075270A (es) 2021-02-26
EA202092451A1 (ru) 2021-03-16
FI3810602T3 (fi) 2023-12-21
HRP20231467T1 (hr) 2024-03-01
HUE064744T2 (hu) 2024-04-28
GEP20227403B (en) 2022-08-10
GB201810092D0 (en) 2018-08-08
CU20200096A7 (es) 2021-08-06
US20200039945A1 (en) 2020-02-06
NI202000092A (es) 2021-03-23
CL2020003219A1 (es) 2021-06-11
BR112020025869A2 (pt) 2021-03-23
PE20210181A1 (es) 2021-01-29
PL3810602T3 (pl) 2024-03-04
CA3101238A1 (en) 2019-12-26
CN112334466A (zh) 2021-02-05
MX2020012723A (es) 2021-05-14
WO2019243491A1 (en) 2019-12-26
LT3810602T (lt) 2024-01-25
MA52948B1 (fr) 2024-02-29
EP3810602B1 (en) 2023-11-01
CR20210032A (es) 2021-02-11
PT3810602T (pt) 2024-01-03
IL279554A (en) 2021-01-31
JP2021529738A (ja) 2021-11-04
DOP2020000249A (es) 2021-02-28
AU2019289888A1 (en) 2020-11-12
UY38270A (es) 2020-01-31
MA52948A (fr) 2021-04-28
RS64932B1 (sr) 2023-12-29
EP4335439A2 (en) 2024-03-13
SI3810602T1 (sl) 2024-02-29
EP3810602A1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
IL279554A (en) compounds
GB2583882B (en) Compounds
GB201805174D0 (en) Compounds
GB201807924D0 (en) Compounds
GB201810581D0 (en) Compounds
GB201814151D0 (en) Compounds
GB201808093D0 (en) Compounds
FI3810633T3 (fi) Yhdisteitä
GB201817083D0 (en) Compounds
GB201810071D0 (en) Compounds
GB201803340D0 (en) Compounds
GB201820887D0 (en) Compounds
GB201818649D0 (en) Compounds
GB201818651D0 (en) Compounds
GB201814167D0 (en) Compounds
GB201801130D0 (en) Compounds
GB201801128D0 (en) Compounds
GB201820989D0 (en) Compounds
GB201819102D0 (en) Compounds
GB201818927D0 (en) Compounds
GB201818698D0 (en) Compounds
GB201818410D0 (en) Compounds
GB201817342D0 (en) Compounds
GB201817292D0 (en) Compounds
GB201817291D0 (en) Compounds